ESTRO 2025 - Abstract Book

S1388

Clinical - Lung

ESTRO 2025

multivariable analysis showed that dose to the base of the heart, especially the sinoatrial node (SAN), correlated with increased RIHD risk (HR=1.02 per 1Gy, 95%CI [1.01-1.03], p<0.001). In the CRT+ICI group, the left ventricle (LV) dose was a significant predictor (1.06 [1.06-1.1], p=0.006). Voxel-based analysis using 1y-survival as endpoint confirmed the impact of cardiac subregion dose on survival for the CRT group, showing the strongest signal near the base of the heart. Sensitivity analyses including only patients treated after introduction of consolidation ICI (2015) yielded similar results.